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Abstract
Heparan sulfate proteoglycans (HSPGs) act as signaling co-receptors by interaction 
of their sulfated glycosaminoglycan chains with numerous signaling molecules. In 
breast cancer, the function of heparan sulfate 2-O-sulfotransferase (HS2ST1), the en-
zyme mediating 2-O-sulfation of HS, is largely unknown. Hence, a comparative study 
on the functional consequences of HS2ST1 overexpression and siRNA knockdown 
was performed in the breast cancer cell lines MCF-7 and MDA-MB-231. HS2ST1 
overexpression inhibited Matrigel invasion, while its knockdown reversed the phe-
notype. Likewise, cell motility and adhesion to fibronectin and laminin were affected 
by altered HS2ST1 expression. Phosphokinase array screening revealed a general de-
crease in signaling via multiple pathways. Fluorescent ligand binding studies revealed 
altered binding of fibroblast growth factor 2 (FGF-2) to HS2ST1-expressing cells com-
pared with control cells. HS2ST1-overexpressing cells showed reduced MAPK signal-
ing responses to FGF-2, and altered expression of epidermal growth factor receptor 
(EGFR), E-cadherin, Wnt-7a, and Tcf4. The increased viability of HS2ST1-depleted 
cells was reduced to control levels by pharmacological MAPK pathway inhibition. 
This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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1  | INTRODUC TION
Heparan sulfate proteoglycans (HSPGs) are glycoproteins of cell sur-
faces and the extracellular matrix (ECM) carrying unbranched poly-
saccharide chains called glycosaminoglycans (GAGs).1-3 HS GAGs 
contain repetitive disaccharide units comprised of alternating uronic 
acids and N-acetyl-glucosamine that are extensively modified by sul-
fation.1-3 HSPGs have crucial regulatory roles in normal physiology 
and pathophysiological conditions, like inflammation, immunomod-
ulation, and tumor onset and progression.3-5 Cell surface HSPGs 
immobilize and regulate ECM turnover, providing cytokines, growth 
factors, and other signaling molecules to receptors on cancer cells to 
support growth, survival, motility, and angiogenesis.1,2,6 They also 
cooperate with integrins and adhesion receptors to facilitate cell-
ECM attachment, cell-cell interactions, and cell motility.2,7
HS biosynthesis begins in the Golgi apparatus with the attach-
ment of a linker tetrasaccharide to a core protein serine residue. 
A backbone of repeated N-acetyl glucosamine (GlcNAc) linked to 
d-glucuronic acid (GlcA) is synthesized on this linker and extended 
by the glycosyltranferases-EXT1 and EXT2.2,8 Subsequent modi-
fication includes N-deacetylation and N-sulfation of some GlcNAc 
units to N-sulfated glucosamine (GlcNS), catalyzed by N-deacetylase 
sulfotransferases (NDSTs), epimerization of some GlcA to iduro-
nate (IdoA) catalyzed by C5-epimerase, followed by 2-O-sulfation 
of uronate residues catalyzed by HS 2-O sulfotransferase (HS2ST1, 
2-OST).1,2 6-O-Sulfation of GlcNAc/GlcNS is catalyzed by HS 6-O 
sulfotransferases, whereas rare 3-O-sulfation modifications of the 
GlcNAc or GlcNS units are mediated by 3-O-sulfotransferases.1,9
Cells normally try to maintain the net overall sulfation profile 
constant.10 A change in sulfation status at one ring position can be 
compensated by sulfation at other positions by tightly regulated ac-
tivities of HS-modifying enzymes in the postulated GAGosome.10-13 
Key structural determinants of HS interaction with cytokines are the 
degree, pattern and clustering of sulfated disaccharides along the HS 
chain,9,14-17 which influence the binding ability of HSPG co-receptors 
to the ligands.
The present study focuses on the role of the HS biosynthetic 
enzyme HS2ST1 in breast cancer progression.12,18,19 Previous studies 
in model organisms have demonstrated a role for 2-O-sulfation in 
cell migration and differentiation through unknown pathways.20,21 
Although HSPGs play an important role in malignancies,22-24 very 
little is known about the specific functional role of HS2ST1 in cancer 
pathogenesis. We show that HS2ST1 upregulation in breast cancer 
cell lines reduces their migratory and invasive behavior due to a de-
crease in epidermal growth factor receptor (EGFR) and E-cadherin 
expression and overall phosphokinase signaling. Phenotypic effects 
are associated with altered binding of growth factors to 2-O sulfated 
HS, and depend on MAPK signaling. These results demonstrate for 
the first time that increased HS2ST1 expression controls the inva-
siveness of breast cancer cells.
2  | MATERIAL S AND METHODS
2.1 | Materials
Medium, fetal calf serum (FCS) and tissue culture supplies were from 
Gibco BRL. Unless stated otherwise, all chemicals were from Sigma.
2.2 | Cell culture
MCF-7 and MDA-MB-231 breast cancer cells were purchased 
from ATCC/LGC Promochem. Cells were stably transfected as de-
scribed25 with a pcDNA3.1 control plasmid (Invitrogen) or a plas-
mid allowing for expression of the open reading frame (1104 bp) of 
human HS2ST1 (NCBI Reference Sequence: NM_012262) in the vec-
tor pReceiver-M02 under the control of the cytomegalovirus (CMV) 
promoter (RZPD/ImaGenes). MDA-MB-231 cells were maintained in 
Dulbecco's Modified Eagle Medium (DMEM) containing 10% FCS, 
1% glutamine, 1% penicillin/streptomycin and 800 µg/mL G418 in a 
humidified atmosphere of 7.5% CO2 in air at 37°C. MCF-7 cells were 
cultured in RPMI-1640 medium containing 10% FCS, 1% glutamine, 
1% penicillin/streptomycin and 800 µg/mL G418 in a humidified at-
mosphere of 5% CO2 in air at 37°C. In some experiments, 10 µmol/L 
U0126 (Cell Signaling Technologies) was used to inhibit the MAPK 
pathway.
2.3 | HS2ST1siRNA knockdown
siRNA knockdown was performed using Dharmafect (Dharmacon) 
and 20 nmol/L validated silencer select siRNA #18569, targeting 
exon 4 of HS2ST1, siRNA #18570, targeting exon 2 of HS2ST1, and 
negative control siRNA #1 (Ambion) according to the manufactur-
er’s instructions. Cellular phenotypes of siRNA-treated cells were 
Moreover, MAPK inhibitors generated a phenocopy of the HS2ST1-dependent delay 
in scratch wound repair. In conclusion, HS2ST1 modulation of breast cancer cell inva-
siveness is a compound effect of altered E-cadherin and EGFR expression, leading to 
altered signaling via MAPK and additional pathways.
K E Y W O R D S
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analyzed after 48 h (PCR) or 72 h (protein-based assays, functional 
assays), respectively.
2.4 | Disaccharide analysis of glycosaminoglycans
GAG isolation was performed from cell pellets as described earlier26 
except for elution of DEAE columns with 2 mol/L NaCl followed by 
desalting on PD MiniTrap™ G-25 columns (GE Healthcare). GAGs 
were digested with 50 mU of chondroitinase ABC (Seikagaku) and 
10% of the total sample directly analyzed by reverse-phase ion-pair-
ing high-performance chromatography (RPIP-HPLC). The remaining 
90% were reapplied to a DEAE column and eluted to remove CS-
disaccharides. The eluted HS pool was split into 2 equal aliquots and 
one incubated without, the other with, a mixture of 0.4 mU each of 
heparin lyases I, II and III (IBEX). Disaccharide separation was per-
formed by RPIP-HPLC as described.26 Peaks were identified by co-
elution with standard CS and HS disaccharides.
2.5 | Cell viability assay
Cell viability was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay essentially as previously de-
scribed.27 Here, 5000 cells were seeded in quadruplets into 96-well 
plates and cultured for 24, 48, or 72 h, respectively. Afterwards, 4 h 
of incubation in the presence of 5 mg/mL MTT followed. Cells were 
lysed by addition of an equal volume of 10% sodium dodecyl sulfate 
(SDS) in 50% N,N-dimethylformamide, pH 4.7, for 16 h, and optical 
density measurement at 595 nm was performed using a microplate 
reader. Cell viability data are shown as percentage viability of vec-
tor/control siRNA-treated cells.
2.6 | Apoptosis assay
Apoptotic cells were identified by flow cytometry using the Annexin 
V test kit (Becton Dickinson), based on their property of binding flu-
orescently labeled annexin V as a result of apoptosis-related mem-
brane inversions. Cells were counterstained with propidium iodide 
to identify late apoptotic/necrotic cells. Fluorescence emission was 
measured at 527 and 675 nm on a flow cytometer (CyFlow Space, 
Partec).
2.7 | Invasion assay
BioCoat Matrigel Invasion Chamber (BD Biosciences) assays were 
performed exactly as described previously.25,27 Briefly, 25 000 cells 
were seeded into invasion filters (BD Biosciences) in a 24-well plate 
format and incubated for another 24 h. Invasion was induced by 
addition of serum-free medium to the upper chamber and of 10% 
FCS-containing medium as chemoattractant to the bottom chamber 
of the invasion chamber for another 24 h (MDA-MB-231) or 48 h 
(MCF-7), respectively, resulting in transmigration of the cells through 
the basement-membrane-like extracellular matrix. Cells in the upper 
chamber were removed with a cotton swab, and cells on the lower 
surface were fixed and stained with Diff-Quik dye (Medion). Excised 
and mounted filter membranes were photographed using a Zeiss 
Axiovert microscope (Zeiss) at ×100 magnification. Relative invasive-
ness was expressed as percentage of the HS2ST1-overexpressing or 
siRNA-treated cells compared with vector/control siRNA-treated 
cells (n > 3).
2.8 | Scratch motility assay
Scratch motility assays were performed as previously described.27 
Confluent cell monolayers were wounded by scraping once horizon-
tally and vertically with a 100 µL pipette tip. Closing of the scratch 
wound was monitored by Nomarski contrast light microscopy and 
documented with a Zeiss Axiophot camera (Zeiss) immediately and 
6 h after wounding. Zeiss Axiovision software (Zeiss) was used to 
calculate the cell-free wounded area. Data are shown as percent-
age of the cell-free area of HS2ST1-manipulated cells compared with 
controls.
2.9 | Migration assay and digital 
holographic microscopy
An inverted microscope (iMIC, Till Photonics) with an attached digi-
tal holographic microscopy (DHM) module28 and an incubator (Solent 
Scientific Ltd.) for stabilized temperature were used for bright-field 
imaging and quantitative digital holographic phase-contrast imaging 
of control and HS2ST1-overexpressing MDA-MB-231 cells seeded 
on laminin-coated Petri dishes. The coherent light source for the re-
cording of digital holograms was a frequency-doubled neodymium-
doped yttrium aluminum garnet (Nd:YAG) laser (Compass 315 M-100, 
Coherent, λ = 532 nm). Experiments were performed in μ-dishes 
(ibidi GmbH) seeded with 3 × 104 cells. Digital holograms of single 
cells were recorded continuously every 3 min. Digitally captured 
hologram reconstruction was performed by spatial phase shifting re-
construction.29 For DHM, the cells were cultured in HEPES-buffered 
DMEM. Three independent single cell analyses were performed and 
representative measurements are shown in the results. Migratory 
behavior of cells was analyzed by automated cell tracking.30
2.10 | Adhesion assay
Here, 96-well plates were coated with 10 µg/mL fibronectin or 
50 µg/mL laminin or 10 µg/mL BSA (negative control) for 16 h at 
4°C and washed twice with wash solution (0.1% BSA in DMEM), fol-
lowed by blocking of nonspecific binding with 0.5% BSA in DMEM at 
room temperature. Adhesion of 2.5 × 104 cells/well was quantified 
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using a photometric methylene blue staining based method as previ-
ously described.7 Cells were released with 2 mmol/L EDTA in PBS, 
washed twice, and resuspended in blocking solution prior to incuba-
tion with the coated wells for 1 h at 37°C. Nonadherent cells were 
removed by 3 washes with PBS. Following fixation of attached cells 
with 3.7% NaCl/PBS-buffered formaldehyde for 30 min, cells were 
stained with 1% methylene blue in 0.01% borate buffer (pH 8.5) for 
30 min. Following 4 washes with borate buffer, the cells were lysed 
in ethanol/0.1 mol/L HCl (1:1), and the released stain was quanti-
fied in a Softmax Microplate reader (Molecular Devices) at 620 nm. 
Data are expressed as percentage of HS2ST1-manipulated cell values 
compared with control cells.
2.11 | Quantitative real-time PCR
Total cellular RNA was isolated using RNA-OLS (OMNI Life Science) 
and reverse transcribed (Advantage First strand cDNA synthesis kit; 
Fermentas). qPCR and melting curve analysis were performed using 
Qiagen QuantiTect SYBR Green PCR kit in a LightCycler. Expression 
of additional mRNAs was analyzed using TaqMan probes on an ABI 
PRISM 7300 Sequence Detection System as described previously 
using the 2−ΔΔCt method after normalization to 18S rRNA.27 The fol-
lowing TaqMan probes were used (see also lifetechnologies.com): 
18S rRNA: hs 99999901_s1; EGFR: hs 00193306_m1; HS2ST1: 
hs_00202138_m1; Wnt 7a: hs 01114990_m1.
2.12 | Western blotting
Western blotting was performed as previously described.7 Briefly, cells 
were lysed in modified RIPA buffer with proteinase inhibitors. 50 µg of 
protein per lane were separated on 10% gels, and electrotransferred 
to Hybond nitrocellulose membranes (Amersham, Pharmacia Biotech). 
For antibody incubations, the membranes were blocked with 5% 
skimmed milk in 0.1% TBS-Tween (TBST) for 1 h at room temperature, 
followed by incubation with the primary antibody overnight at 4°C. 
Antibodies and dilutions are listed in Table 1. After washing in TBST 
buffer 3 times, the membranes were incubated for 30 min at room 
temperature with horseradish peroxidase-conjugated secondary anti-
bodies in blocking buffer. The membranes were washed and treated 
with enhanced chemiluminescence detection reagents (Amersham 
Pharmacia Biotech) for 1 min and exposed to Hyperfilm-ECL. For de-
tection of the total forms of phosphorylated proteins, and for detection 
of the housekeeping control protein tubulin, membranes were stripped 
with 0.2 mol/L glycine buffer (pH 2.5), washed, reincubated with pri-
mary antibody, and subjected to the procedure described above.
2.13 | Phosphokinase array
Human phosphokinase array was performed following manufactur-
er's instructions (R&D Systems). 300 μg of protein from control and 
HS2ST1-overexpressing cells was analyzed in a panel of phospho-
rylation profiles of kinases.
2.14 | Analysis of biotinylated FGF-2 binding by 
flow cytometry
Binding of basic fibroblast factor (FGF-2) to 4 × 106 EDTA-detached 
cells/mL was analyzed by flow cytometry employing FluorokineR 
Biotinylated human FGF-2 and avidin-FITC reagent (R&D Systems) 
according to the manufacturer’s instructions.
2.15 | Heparan sulfate purification from cells for 
Fourier transform infrared (FTIR) analysis
Here, ~2.5 × 107 cells per sample were washed in PBS, scraped from 
the flasks, pelleted and lyophilized. The lyophilized cell pellets were 
separately suspended in 2 mL of 0.1 mol/L sodium acetate buffer 
(pH 5.5) containing 1% of papain, 5 mmol/L EDTA and 5 mmol/L 
cysteine and incubated at 60°C overnight. This was then centri-
fuged at 2000 g for 10 min at room temperature, the supernatant 
was separated. The clear supernatants from different samples were 
ethanol precipitated and suspended in 0.1 mol/L NaCl. The solution 
was applied on a DEAE column equilibrated with sodium phosphate 
buffer (pH 6.0) containing 0.15 mol/L NaCl. Fractions were eluted 
with 1.0 mol/L NaCl in the same buffer, desalted with HiTrap™ 
TA B L E  1   Antibodies used in this study
Antibody
Working 
dilution Manufacturer
Rabbit polyclonal anti-phospho-
Thr202/Tyr204 p44/42 MAPK
1:1000 Cell Signalling
Rabbit polyclonal anti-p44/42 
MAPK
1:1000 Cell Signalling
Mouse anti-human E-cadherin, 
clone 36
1:1000 Becton and 
Dickinson 
Biosciences
Rabbit polyclonal anti-EGFR 1:1000 Cell Signalling
Rabbit monoclonal anti-human 
TCF4
1:1000 Cell Signalling
Rabbit polyclonal anti-HS2ST1 1:1000 Cell Signalling
Rabbit polyclonal anti-phosphor- 
Thr180/Tyr182 p38 MAPK
1:1000 Cell Signalling
Rabbit polyclonal anti-p38 MAPK 1:1000 Cell Signalling
Mouse anti-human α-Tubulin, clone 
B-5-1-2
1:4000 Sigma-Aldrich
Horseradish peroxidase-conjugated 
goat-anti-mouse IgG
1:10 000 Merck-
Millipore
Horseradish peroxidase-conjugated 
goat-anti-rabbit IgG
1:2000 Merck-
Millipore
Horseradish peroxidase-conjugated 
rabbit-anti-goat IgG
1:5000 Merck-
Millipore
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desalting column, lyophilized, and resuspended in 15 μL 0.03 mol/L 
acetate buffer (pH 7.0) with 1.0 mU/μL chondroitin ABC (in 10 μL 
cABC buffer, pH 8.0) to degrade chondroitin sulfate and hyaluronan. 
The mixture was incubated at 37°C overnight, lyophilized and the 
enzymatic reaction was inactivated at 96°C for 2 min before freeze 
drying. Samples were resuspended in Milli-Q water to load onto the 
HPLC for separation of HS.
2.16 | Extraction of total GAGs from 
conditioned medium
Cells underwent starvation in growth medium without serum for 
24 h at 37°C with 5% CO2 in air. Then, 10 mL of conditioned medium 
(CM) were centrifuged to remove cell debris. CM supernatants were 
concentrated using a Vivaspin™ column with a 10 000 Da MWCO 
(GE Healthcare Bio-Sciences AB), and incubated overnight at 37°C 
with a pronase (Cat. No. P8811-1G, Sigma-Aldrich) to digest all pro-
teins. Proteinase deactivation was performed by addition of NaCl 
(50 nmol/L) and incubation at 100°C for 1 min. After cooling, cen-
trifugation was performed to pellet digested proteins. GAGs were 
precipitated from the supernatant by addition of saturated sodium 
acetate and incubation at 4°C for 3 h. Precipitated GAGs were air-
dried and resuspended in sterile distilled water. For each cell line, 3 
independent biological replicates were analyzed.
2.17 | FTIR spectroscopy of extracted GAGs
Here, 5 µL of resuspended extracted GAGs (1 µg/µL) were deposited 
in triplicate onto a high- throughput 384-well silicon plate, air-dried, 
and analyzed with a high-throughput screening HTS-XT extension 
coupled to a Tensor 27 FTIR spectrometer (Bruker Optics GmbH). 
The FTIR acquisitions of the samples were performed in trans-
mission mode, in the spectral range 4000-400 cm−1, at a spectral 
resolution of 4 cm−1 with 64 scans. Before each sample measure-
ment, the silicon plate background was recorded and automatically 
removed from the sample signal. One spectrum was obtained from 
each well. Acquisition and pre-processing were performed with the 
OPUS software (Version 6.0, Bruker Optics).
2.18 | Spectral data pre-processing and analysis
Before pre-processing, some spectra were discarded after spectral 
quality test. For FTIR spectral analysis, a baseline correction was per-
formed and a second derivative was calculated to increase the dif-
ferences between spectra. A vector normalization was applied for 
spectral comparison. Then, data were processed with multivariate sta-
tistical exploratory techniques like hierarchical cluster analysis (HCA) 
and principal component analysis (PCA). These clustering methods 
based on distance calculation and variance analysis respectively, al-
lowed for analysis how spectra group together in an unsupervised 
way. These 2 analyses were performed in the 1350-900 cm−1 spec-
tral range. The complete workflow for GAGs analysis by FTIR high-
throughput spectroscopy has been reported previously.31
2.19 | Statistical analysis
Data were expressed as mean ± SEM or SD, as indicated. Statistical 
analysis was performed using the Sigma Stat 3.1 software (Systat 
Software). An unpaired t test was used when groups passed the nor-
mality test, otherwise, the Mann-Whitney U test was used. A two-
sided P-value < .05 was considered statistically significant.
3  | RESULTS
3.1 | Confirmation of stable overexpression and 
transient siRNA knockdown of HS2ST1
To study the functional impact of increased HS2ST1 expression, 
the metastatic triple-negative cell line MDA-MB-231 and the less 
dedifferentiated and less invasive hormone-receptor-positive cell 
line MCF-7 were stably transfected with a control vector and a 
plasmid overexpressing HS2ST1 under the control of a strong CMV 
promoter, respectively. To ensure that the observed phenotypic end 
points are due to increased HS2ST1 expression and not to other mo-
lecular mechanisms, a complementary transient siRNA knockdown 
approach was implemented. In addition, key experiments were con-
firmed using independent overexpressing clones (see Figure S1). 
qPCR analysis showed an 8-11-fold increase in mRNA expression 
of HS2ST1 (Figure 1A and Figure S1A) and up to 90% decrease in 
its expression upon siRNA knock down (Figure 1B). The change in 
HS2ST1 expression was confirmed at the protein level by western 
blotting (Figure 1C,D).
3.2 | FTIR discrimination of HS2ST1-overexpressing 
cells based on extracted GAGs
Taking into account the specific spectral signatures obtained from 
standard GAG molecules and GAG mixtures32,33 and from cells 
based on their capacity for GAG synthesis,34 FTIR measurements 
were undertaken to characterize extracted GAGs from the CM of 
HS2ST1-overexpressing vs control cells. The mean normalized FTIR 
spectra obtained of extracted GAGs showed differences between 
MCF-7 and MDA-MB-231 cell lines in the 1800-900 cm−1 spectral 
range. These differences were more visible in the 1350-800 cm−1 
spectral range (GAGs absorption region). This region was selected 
for exploratory chemometrics analysis. Moreover, in the 1350-
800 cm−1 spectral range, extracted GAGs from control and HS2ST1-
overexpressing MCF-7 or MDA-MB-231 cells could be easily 
discriminated. HCA and PCA were performed on second derivative 
spectra in the 1350-800 cm−1 spectral range. HCA results displayed 
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in Figure 1E showed that spectra of GAGs extracted from CM of the 
same cell type were grouped in the same cluster. They exhibited a 
low degree of heterogeneity, indicating a good reproducibility, and 
a low intra-group variability, which was sufficient to distinguish be-
tween MCF-7 and MDA-MB-231 CM. Moreover, CM from control 
and HS2ST1-transfected cells could be discriminated. To confirm 
these observations, a second chemometric method based on PCA 
analysis was carried out. Figure 1F shows the PCA score plot of the 
CM of each cell type using the first 2 principal components (PCs) 
carrying the highest explained variance. The first PC (PC1) carried 
89.2% of the total variance and allowed a clear separation between 
CM from MCF-7 and MDA-MB-231 cell lines. These results also 
showed that PC2, representing 6.5% of the total variance, allowed 
the separation of CM between control and HS2ST1-overexpressing 
cells. This is clear for MDA-MB-231 cell types while a combina-
tion of PC1 and PC2 seemed to be necessary to delineate between 
MCF-7 cell types. Disaccharide analysis of HS2ST1-overexpressing 
MDA-MB-231 (Figure 1G) and MCF-7 (Figure 1H) cells also revealed 
a slight increase of 2-O-sulfated HS structures compared with their 
corresponding vector controls.
F I G U R E  1   Overexpression of HS2ST1 results in altered FTIR spectra. A, B, qPCR (A, B) and western blotting (C, D) confirm stable 
transfection (A) and siRNA knockdown (B) of HS2ST1in MDA-MB-231 and MCF-7 cells. A, B, N = 9, Error bars = SEM, ***P < .001. C, D, 
Upper panels, plasmid-based overexpression; lower panels, siRNA knockdown. E, Hierarchical cluster analysis of FTIR spectra of GAGs from 
conditioned medium (CM) of control and HS2ST1-overexpressing cells. F, Principal component analysis score plot of FTIR spectra of GAGs 
extracted from CM of control and HS2ST1-overexpressing cells. E, F, Analysis was performed on second derivative spectra in the 1350-
800 cm−1 spectral range. G, H, Biochemical RPIP-HPLC characterization of HS disaccharides of HS2ST1-transfected cells. Peaks co-eluting 
with standard disaccharides are labeled as N-acetylglucosamine (NAc), N-sulfated glucosamine (NS) and sulfate group at indicated position 
(S). N = 2 independent analyses
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3.3 | HS2ST1 modulates breast cancer cell 
migration, cell-ECM adhesion, and invasiveness
Migration and cell-ECM adhesion are critical steps during cancer 
cell invasion that are regulated by HSPGs.25,35,36 Hence, we tracked 
the migratory behavior of HS2ST1-overexpressing MDA-MB-231 
cells by time lapse microscopy and observed a decrease in their ca-
pability to migrate on laminin by ~25% (Figure 2A,B). These results 
were consistent with data obtained by scratch wound assay, where 
HS2ST1-overexpressing cells displayed a significant delay of 23%-
30% in wound closure (Figure 2C and Figure S1B). In vitro adhesion 
assays revealed that HS2ST1-overexpressing MDA-MB-231 cells 
showed significantly increased adhesion of 3.0-fold to fibronectin 
and ~3.8-fold to laminin, while MCF-7 showed a ~5.4-fold increase 
toward fibronectin compared with ~5.7-fold toward laminin substrate 
(Figure 2D-G). In contrast, HS2ST1-depleted MDA-MB-231 cells 
displayed a 33% decrease in adhesiveness to fibronectin and ~45% 
decrease to laminin compared with the controls (Figure 2E,G). The ef-
fect was more pronounced in MCF-7 cells, where a decrease of 70% 
to fibronectin and 66% to laminin was observed (Figure 2E,G). We 
next investigated the cellular capacity to invade through Matrigel, a 
basement membrane-like ECM. While invasion decreased in HS2ST1-
overexpressing MCF-7 cells and in the highly metastatic MDA-MB-231 
cells (Figure 2H,I), it dramatically increased upon HS2ST1 knockdown 
in MDA-MB-231 (Figure 2H,J). In contrast, siRNA knockdown of 
HS2ST1 in MCF-7 cells did not affect invasiveness (Figure 2J). We no 
F I G U R E  2   HS2ST1 modulates breast cancer cell adhesion, migration and invasion. A, B, DHM time lapse analysis reveals lower migration 
of HS2ST1-transfected MDA-MB-231 cells (n = 13) compared with vector controls (n = 16), on laminin coating. A, Migration tracks. B, 
Quantification revealing a c. 30% decrease in the migration distance. N = 3, error bars = SEM. C, Scratch wound closure assay reveals slower 
migration of HS2ST1-transfected MDA-MB-231 and MCF-7 cells compared with controls. ***P < .001, **P < .01; N ≥ 9, error bars = SEM. D-G, 
Cell adhesion to fibronectin and laminin is increased upon HS2ST1 overexpression (D, F) and decreased upon HS2ST1 depletion (E, G). N = 18, 
Error bars = SEM, ***P < .001, **P < .01, *P < .05. H-K, Impact of HS2ST1 on invasive behavior of breast cancer cells in Matrigel invasion 
chamber assays. H, Representative images of Matrigel matrix filters. t = 24 h (highly invasive MDA-MB-231), t = 48 h (low invasive MCF-7). I, 
HS2ST1 overexpression significantly inhibits invasion. J, siRNA knockdown of HS2ST1 promotes MDA-MB-231 invasiveness, while invasion is 
not affected in MCF-7 cells. ***P < .001, **P < .01, N ≥ 6, error bars = SEM. K, Vector controls and HS2ST1-overexpressing MDA-MB-231 cells 
displayed no difference in their invasion capacity upon prior HS degradation with 0.5 U/mL heparin lyase III (4 h). N = 6, error bars = SEM
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longer observed a difference in the invasive potential of control and 
HS2ST1-overexpressing cells after HS digestion with heparin lyase III, 
suggesting that indeed the HS and its modification correlate to the 
observed invasive phenotype (Figure 2K).
3.4 | HS2ST1 overexpression reduces breast 
cancer cell viability and signal transduction via 
multiple pathways
HSPGs play an important role as signaling co-receptors.1,2,7,37,38 To 
test the impact of altered HS2ST1 expression, cell viability was as-
sessed by MTT assay over a time course of 72 h (Figure 3A). While 
cell viability was consistently decreased upon HS2ST1 overexpression 
in both cell lines at all timepoints after 24, 48 and 72 h, respectively, 
MDA-MB-231 cells were more strongly affected by HS2ST1 overex-
pression compared with MCF-7 cells (Figures 3A and S1C). The HS2ST1-
dependent decrease in viability was not due to increased apoptosis, as 
flow cytometric analysis of annexin V binding did not reveal signifi-
cant differences between HS2ST1-overexpressing and control breast 
cancer cells (Figure S1D). Phosphokinase array screening revealed a 
net overall decrease in the phosphorylation status upon overexpres-
sion of HS2ST1 in MDA-MB-231 cells. Phosphorylation of p38 MAPK, 
Erk 1/2 (p44/42 MAPK), JNK 1/2/3, EGFR, Akt, and p53, along with 
several other proteins, was decreased in HS2ST1-overexpressing 
compared with control cells, (Figure 3B and Table 2), indicating an 
important general role of HS2ST1 in signal transduction. HS2ST1 over-
expression led to decreased activation of the p44/42 and p38 MAPK 
signaling pathways (Figures 3C,D and S1E,F) in MDA-MB-231 cells. 
HS2ST1 knockdown resulted in similar constitutive activation levels of 
p44/42 MAPK in control and HS2ST1-overexpressing MDA-MB-231 
cells (Figure 3E). In contrast, siRNA knockdown of HS2ST1 activated 
p44/42 MAPK signaling in MCF-7 cells (Figure 3F).
3.5 | Alterations in the migratory and 
invasive behavior are associated with changes 
in the expression of the cell-cell adhesion molecule 
E-cadherin and the transcription factor TCF-4
The prognostically relevant cell-cell adhesion molecule E-cadherin is 
co-expressed with the HSPG Syndecan-1 in early breast cancer and 
F I G U R E  3   HS2ST1 affects cell 
viability and modulates multiple signaling 
pathways. A, HS2ST1 upregulation 
significantly reduces cell viability over 
a time course of 24-72 h (MTT assay), 
having a stronger impact in MDA-MB-231 
cells compared with MCF-7 cells. *P < .05, 
**P < .01, ***P < .001, N = 6, error 
bars = SEM. B, Phosphokinase array blot 
showing an overall decrease in signaling 
upon HS2ST1 overexpression compared 
with controls. C, D, Western blot analysis 
reveals that constitutive p44/42 (C) and 
p38 (D) MAPK activation were decreased 
in HS2ST1-overexpressing MDA-MB-231 
cells. E, Basal p44/42 MAPK was activated 
upon HS2ST1 siRNA knockdown in 
MDA-MB-231 cells raising the activation 
levels similar to the controls. F, siRNA 
knockdown of HS2ST1 activates basal 
MAPK in MCF-7 cells compared with 
controls where the pathway is not active. 
Tubulin was used as a loading control. 
N = 9
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regulates the invasive capability of cells.39-42 While E-cadherin expres-
sion was increased in HS2ST1-overexpressing cells compared with 
controls, its expression was downregulated upon HS2ST1 knockdown 
in both cell lines (Figure 4A-D). HSPGs modulate the Wnt/β-catenin 
signaling pathway, which regulates cell survival, proliferation, and 
differentiation.43,44 Western blot analysis of the Wnt effector Tcf4 
(Tcf7l2) confirmed strong downregulation in HS2ST1-overexpressing 
MDA-MB-231 and MCF-7 cells compared with controls (Figure 4E,F). 
Pharmacological inhibition of constitutive MAPK signaling in 
MDA-MB-231 cells expressing a different HS sulfotransferase, 
TA B L E  2   Relative activation of kinases and signaling receptors in HS2ST1 and control vector-transfected cell lines according to 
phosphokinase array screening
Number Protein Phosphorylation site
HS2ST1-overexpressing cells
MDA-MB 231 MCF-7
1 C,D p 38 alpha T180/Y182 Down Down
1 E,F ERK 1/2 T202/Y204, T185/Y187 Down Down
1 G,H JNK 1/2/3 T183/Y185, T221/Y223 Down Down
2 C,D EGFR Y1086 Down Down
2 E,F Msk 1/2 S376/S360 Down Down
2 G,H AMPKα1 T183 Down Down
2 I,J Akt 1/2/3 S473 Down No change
2 K,L Akt 1/2/3 T308 Down No change
2 M,N P53 S46 Down Slightly down
3 A,B TOR S2448 Slightly down No change
3 E,F HSP27 S78/S82 Down Slightly down
3 G,H AMPKα2 T172 Slightly down No change
3 I,J β-Catenin — Down Slightly down
3 K,L P70 S6 kinase T389 Down No change
3 M,N P53 S15 Down Slightly up
3 O,P c-Jun S63 Down Up
4 A,B Src Y419 Slightly down Slightly down
4 C,D Lyn Y397 Down No change
4 E,F Lck Y394 Down No change
4 G,H Stat2 Y689 Slightly down No change
4 I,H Stat 5a Y694 Down Slightly down
4 K,L P70 S6 kinase T421/S424 Down Slightly up
4 M,N RSK 1/2/3 S380/S386/S377 Down Slightly up
4 O,P eNOS S1177 Down No change
5 A,B Fyn Y420 Down No change
5 C,D Yes Y426 Down No change
5 G,H Stat 6 Y641 Down Down
5 I,J Stat 5B Y699 Down Down
5 K,L Stat 3 Y705 Down Slightly down
5 M,N P27 T198 No change Not expressed
5 O,P PLC-γ1 Y783 Down Slightly up
6 A,B Hck Y411 Down Slightly down
6 C,D Chk-2 T68 Down No change
6 E,F FAK Y397 Slightly down No change
6 G,H Stat 5 a/b Y694/Y699 Down No change
6 K,L Stat 3 S727 Down No change
6 M,N Wnk 1 T60 Down No change
6 O,P Pyk 2 Y402 Down No change
7 C,D PRAS 40 T246 Down Down
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HS3ST2, abolished the increased Tcf4 expression,45 suggesting a cross-
talk between the 2 pathways. Moreover, HS2ST1 overexpression led to 
elevated Wnt 7a mRNA expression (Figures 4G and S1G).
3.6 | HS2ST1 regulates the expression of epidermal 
growth factor receptor 
EGFR expression is frequently elevated in breast cancer,46 and its 
activation was affected by HS2ST1 according to our phosphokinase 
array screening. qPCR analysis revealed a significant decrease in EGFR 
mRNA expression levels in HS2ST1-overexpressing cells while we ob-
served an increased EGFR mRNA expression upon HS2ST1 knockdown 
(Figures 5A,B and S1H). These data were confirmed at the protein level 
by western blot analysis (Figure 5C,D). We next tested if altered ex-
pression of HS2ST1 affected the activation of MAPK signaling in the 
presence of specific growth factors. For this purpose, serum-starved 
HS2ST1-overexpressing MDA-MB-231 cells were stimulated with EGF, 
which resulted in a moderate increase in MAPK activation due to the 
known constitutive activation status45 in this cell line (Figure 5E). In 
HS2ST1-overexpressing cells, constitutive and early EGF-induced 
MAPK activation were reduced compared with controls (Figure 5E). 
In MCF-7 cells, where the pathway is not constitutively active,45 EGF 
activated p44/42 MAPK after 5 min of stimulation, whereas MAPK ac-
tivation was reduced in HS2ST1-overexpressing cells (Figure 5F).
3.7 | Increased 2-O-sulfation affects binding of FGF-2 
to HS and FGF-2-induced p44/42 MAPK activation
In breast and colon cancer, HSPGs modulate basic fibroblast 
growth factor (FGF-2)-mediated MAPK signaling.25,46 FGF-2 sign-
aling is effectively inhibited by 2-O- and N-sulfated HS oligosac-
charides competing with cellular HS for binding to FGF-2.47-49 In 
light of these findings, binding of FGF-2 to control and HS2ST1-
overexpressing cells was analyzed by flow cytometry by in vitro 
binding of fluorescently labeled FGF-2. The results were compa-
rable as the HS2ST1-overexpressing cells showed in both cell lines 
a ~20% reduced weaker binding of FGF-2 to HS compared with 
the controls (Figure 6A). Stimulation of HS2ST1-overexpressing 
F I G U R E  4   HS2ST1 expression affects 
the expression of E-cadherin, Tcf4, 
and Wnt 7a. A, B, Western blot shows 
increased E-cadherin expression upon 
HS2ST1 overexpression. C, D, HS2ST1 
siRNA knockdown decreases E-cadherin 
expression. E, F, HS2ST1 overexpression 
leads to decreased expression of the Wnt-
related transcription factor Tcf4. G, qRT-
PCR reveals upregulation of WNT-7a in 
HS2ST1-overexpressing cells. ***P < .001, 
N ≥ 6, error bars = SEM
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MDA-MB-231 cells with FGF-2 resulted in a weaker activation of 
the p44/42 MAPK signaling pathway compared with control cells 
(Figure 6B). In MCF-7 cells, FGF-2 activated the MAPK signaling 
in both control and HS2ST1-overexpressing cells, yet, the over-
all activation status of HS2ST1-overexpressing cells was lower 
than the controls (Figure 6B). To link the observed alterations in 
growth factor binding and mitogenic signaling to the phenotypic 
changes induced by altered HS2ST1 expression, we evaluated cell 
viability and scratch wound repair in the absence or presence of 
the MAPK pathway (MEK1/MEK2) inhibitor U0126. siRNA deple-
tion of HS2ST1 resulted in increased viability of MDA-MB-231 
(Figure 6C) and MCF-7 cells (Figure 6D), which was reduced to con-
trol levels by U0126, suggesting a role for MAPK signaling in the 
HS2ST1-dependent process. In addition, MAPK inhibition gener-
ated a phenocopy of the delay in scratch wound motility observed 
in HS2ST1-overexpressing MDA-MB-231 cells (Figure 6E). Overall, 
these results indicated that altered cell behavior in HS2ST1-
misexpressing breast cancer cells is associated with altered ligand 
binding and cellular signaling.
4  | DISCUSSION
In this report we demonstrate a novel role for HS2ST1 in modulating 
breast cancer cell invasiveness via central signaling pathways includ-
ing MAPK and Wnt (Figure 6F). Our findings are in line with studies 
in glioma, indicating a downregulation of HS2ST1 and other HS sul-
fotransferases.50 Mechanistically, HSPGs modulate MAPK signaling, 
promoting proliferation, migration, and invasion.45,51-53 In our model 
cell lines, this pathway is constitutively active in MDA-MB-231 cells, 
but not in MCF-7.51,54 Phosphorylation of Erk 1/2 (p44/42 MAPK) 
was less evident in HS2ST1-overexpressing MDA-MB-231 cells 
F I G U R E  5   HS2ST1 modulates 
EGFR expression and growth factor-
mediated activation of p44/42 MAPK in 
breast cancer cells. A, qRT-PCR reveals 
downregulation of EGFR mRNA expression 
level in HS2ST1-overexpressing breast 
cancer cells. B, HS2ST1 siRNA knockdown 
upregulates EGFR mRNA expression. 
***P < .001, **P < .01, N ≥ 6, error 
bars = SEM. C, Western blot showing 
decreased EGFR protein expression 
compared with controls in HS2ST1-
overexpressing cell lines (upper panels), 
whereas EGFR expression is increased 
upon HS2ST1 siRNA knockdown (D). E, F, 
HS2ST1-overexpressing MCF-7 cells show 
a decreased response to EGF stimulation. 
Serum-starved vector and HS2ST1-
transfected cells were stimulated with 
100 ng/mL EGF for 0, 5, and 10 min. Here, 
25 µg of cell lysate/lane were analyzed 
by western blotting for phospho-p44/42 
MAPK, p44/42 MAPK, and the loading 
control α-tubulin. Compared to controls, 
EGF treatment slightly decreased 
p44/42 MAPK activation as a readout 
of EGF-induced signaling in HS2ST1-
overexpressing MCF-7 cells. The signaling 
response was attenuated to a lower 
extent in HS2ST1-overexpressing MDA-
MB-231 cells
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F I G U R E  6   Altered HS2ST1 expression affects FGF-2 binding, FGF-2-induced MAPK signaling, and MAPK-dependent cell viability and 
migration. A, HS2ST1-overexpressing breast cancer cells show reduced cell surface binding of biotinylated FGF-2. Flow cytometry, reveals 
a decrease of 20% and 30% in the binding efficiency of FGF-2 to HS2ST1-overexpressing MDA-MB-231 and MCF-7 cells compared with 
controls. Right panel, representative measurement (MCF-7 cells). ***P < .001, N = 3, error bars = SEM. B, HS2ST1-overexpression attenuates 
FGF-2-induced MAPK activation. Serum-starved vector and HS2ST1-transfected cells were stimulated with 20 ng/mL FGF-2 for a 0-30 min 
time course and 25 µg of cell lysate/lane were analyzed by western blotting for phospho-p44/42, p44/42 and the loading control α-tubulin. 
C, D, HS2ST1 siRNA knockdown enhances breast cancer cell viability in an MAPK-dependent manner. MDA-MB-231 (C) and MCF-7 (D) 
cells were subjected to control or HS2ST1 siRNA treatment in the absence or presence of the MAPK inhibitor U0126. While HS2ST1 siRNA 
knockdown significantly enhanced breast cancer cell viability, this effect could be reduced to control levels by MAPK inhibition. *P < .05, 
N = 6, error bars = SEM. E, HS2ST1 overexpression and MAPK inhibition by the MAPK inhibitor U0126 delay scratch wound repair in 
MDA-MB-231 cells. MAPK inhibition generates a phenocopy of HS2ST1 overexpression. *P < .05, N ≥ 3, error bars = SEM. F, Model of the 
tumor-suppressive role of HS2ST1 in breast cancer. High levels of HS2ST1 resulted in structural changes in HS and altered growth factor 
binding, which resulted in attenuated signaling through the MAPK and additional pathways. Reduced signaling and expression of E-cadherin 
and EGFR was associated with reduced viability, adhesion, migration, and invasion of breast cancer cells
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compared with the controls, correlating with the reduced invasive 
phenotype. In MDA-MB-231 cells, knockdown of HS2ST1 did not 
result in a further increase in p44/42 MAPK activation, possibly 
because this pathway is already strongly constitutively active in 
these cells.54 In contrast, in MCF-7 cells, HS2ST1 knockdown was 
sufficient to activate this pathway, possibly because altered HS sul-
fation may have affected the binding and presentation of mitogens 
to a broad range of receptors, thus acting as a co-receptor and en-
hancing signaling through the MAPK pathway upon ligand engage-
ment.1,2,4 Surprisingly, siRNA knockdown of HS2ST1 did not enhance 
invasiveness of MCF-7 cells in our Matrigel chamber assay. It has 
been shown that stimulation of MCF-7 cells with growth factors 
such as TGF-α only leads to transient activation of MAPK signal-
ing and cell migration, whereas the same induces sustained MAPK 
activation, enhanced cell motility, and increased in vitro invasion of 
MDA-MB-231 cells,51 which may be an underlying cause for our ob-
servation. Another MAPK, p38, was also less activated in HS2ST1-
overexpressing MDA-MB-231 cells supporting the observed 
phenotype. Intriguingly, phosphokinase array data revealed an over-
all HS2ST1-dependent decrease in the phosphorylation status of 
p38, Erk 1/2, EGFR, Akt, JNK and several other proteins (see Table 2). 
The reduced overall signaling is in accordance with the observed de-
creased invasiveness of HS2ST1-overexpressing cells. EGFR, known 
to be overexpressed and activated in approximately 20%-25% of 
cancers,55 acts as a central point for the activation and crosstalk with 
many signaling pathways relevant to tumor migration and invasion.56 
MAPK and other kinases like phosphatidylinositol-3-kinase (PI3-K) 
act downstream of EGFR activation, promoting tumor cell migration 
and invasion.50,57-59 In addition, decreased activation or inhibition of 
p38 MAPK decreases breast cancer metastasis.60
Altered MAPK activation resulted in decreased expression 
of the Wnt pathway-related transcription factor Tcf4 (Tcf7/
l2) in HS2ST1-overexpressing MDA-MB-231 cells. Indeed, a HS-
dependent crosstalk between Wnt and MAPK pathways modu-
lates invasiveness via regulation of several downstream targets 
such as proteases, cadherins, and ECM components.45 Apart 
from Tcf4, Wnt 7a was transcriptionally upregulated in HS2ST1-
overexpressing cells. Wnt signaling has been linked to the mam-
malian target of rapamycin (mTOR) pathway,61 which promotes 
cancer cell invasion.62 Notably, reduced mTOR signaling is asso-
ciated with increased hormone resistance in MCF-7 cells,63 while 
MAPK pathway activation may enhance the sensitivity of these 
cells to estradiol.64 As the triple-negative cell line MDA-MB-231 
does not express estrogen receptor alpha, differential activation 
of these pathways may have contributed to the partially divergent 
impact of HS2ST1 on hormone receptor-positive and hormone 
receptor-negative cells. Previous studies have demonstrated the 
positive regulation of E-cadherin expression by Wnt 7a in lung can-
cer cells.65 E-cadherin acts as a tumor suppressor because of its 
role in establishing cell-cell adhesion66 and is known to be co-ex-
pressed along with syndecan-1 HSPG in early stages of breast 
cancer.42 Here, we show that HS2ST1 overexpression directs up-
regulation of E-cadherin, thereby establishing cell-cell adhesion, 
while the knockdown suppresses its expression, which is associ-
ated with cancer progression and metastasis.67 Upregulation of 
E-cadherin in HS2ST1-overexpressing MCF-7 cells may have also 
had an impact on Tcf-4, as the cytoplasmic domains of E-cadherin 
bind to beta-catenin,68 which would then not be available to acti-
vate Tcf-4. Notably, decreased E-cadherin expression and loss of 
cell-cell adhesion were also observed in HS2ST1 morphant cells of 
zebrafish embryos.69 Reduction of cell-cell adhesion is accompa-
nied by decreased cell adhesion to ECM ligands70 and it is known 
that cell-cell and cell-matrix adhesion directly determine cell mo-
tility.2,35 We show a crucial role of HS2ST1 in modulating cell-ECM 
adhesion as tumor cell-matrix adhesion is considered to be a key 
event regulating metastasis.36,71 Increased binding of HS2ST1-
overexpressing cells to fibronectin and laminin correlates with the 
observed migration and invasion phenotypes suggesting that the 
altered surface structure (as determined by FTIR analysis) reduces 
ECM adhesion, thereby facilitating cell migration. This finding is 
supported by a previous study in which increased adhesion to 
laminin inhibited cell movement.72
EGFR, one of the major upstream modulators of MAPK pathway 
is often overexpressed in more aggressive triple-negative breast 
cancers46 and is associated with poor prognosis and large tumor 
size.73,74 EGFR acts as a central point for many signaling pathways, 
including G-protein coupled receptor signaling, which transactivates 
EGFR, inducing invasion.75,76 It regulates epithelial-to-mesenchymal 
transition via its downstream regulator-ERK inducing mesenchy-
mal motility and invasion in cancer cells.77 The HS2ST1-dependent 
changes in EGFR expression contribute to changes in invasive be-
havior of triple-negative MDA-MB-231 cells.
Previous studies have demonstrated that HS modulates signal-
ing by growth factor binding25,49 and that 2-O-sulfated HS oligo-
saccharides effectively bind to FGF-2.47 It has been shown that HS, 
which binds to FGF but does not bind to the fibroblast growth fac-
tor receptor (FGFR), acts as a competitor.17 We could demonstrate 
weaker binding of FGF-2 to HS2ST1-overexpressing cells, which 
may be one of the reasons for the observed reduction in signaling 
in these cells.78,79 Moreover, the formation of FGF-FGFR signaling 
complexes is generally believed to be promoted by HS chains that 
bind to both growth factors and receptors.80,81 The smaller effect 
of FGF-2 binding to cell surface HS compared with control cells 
could be due to steric hindrance of HS on the cell surface and/or to 
a conformational change in HS,82 compared with isolated HS, for 
which binding sites are more freely available. Mechanistically, this 
explains the overall phenotypic end points obtained as a result of 
modifying HS specifically at the 2-O position.
A novel and non-invasive approach for analyzing sulfated GAGs 
from CM led to good discrimination between control and HS2ST1-
overexpressing cells. By focusing the analysis on the sulfate ab-
sorption region, HS2ST1-transfected cell CM was different from 
the control counterparts both for MDA-MB-231 and MCF-7 cells, 
although more marked for MDA-MB-231. This suggests that an FTIR 
spectroscopic approach could be used as a rapid monitoring method 
for screening CM.
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In conclusion, this study provides evidence for the promising 
role of HS2ST1 in modulating breast cancer cell invasiveness via 
modulating EGFR and additional signaling pathways (Figure 6F). 
This report is the first to reveal the impact of an HS modifier en-
zyme, HS2ST1, in controlling the invasiveness of breast cancer 
cells in vitro. Further in vivo and clinical studies in this direction 
will be of great interest and importance for future potential cancer 
therapeutics.
ACKNOWLEDG MENTS
The authors thank Birgit Pers, Luisa Pohl, and Steffi Ketelhut for 
expert technical assistance, Dorothe Spillmann for performing GAG 
Disaccharide analysis, Mariana Stelling for kind assistance with HS 
purification, and Stephanie Beel for assistance with inhibitor studies. 
Funding was provided by Deutsche Forschungsgemeinschaft DFG 
IRTG “Molecular and Cellular GlycoSciences” Grant GRK 1549 (to 
AVK, SKK, FMG and MG), Deutscher Akademischer Austauschdienst 
DAAD Grant PROBRAL 54387857 (to MG and MSGP), and a WWU 
fellowship of the University of Münster (to JMM).
DISCLOSURE
The authors have no conflict of interest.
ORCID
Stéphane Brézillon  https://orcid.org/0000-0001-7954-8340 
Valérie Untereiner  https://orcid.org/0000-0002-3360-0171 
Ganesh Dhruvananda Sockalingum  https://orcid.
org/0000-0003-3160-4678 
Hossam Taha Mohamed  https://orcid.
org/0000-0003-1989-5783 
Björn Kemper  https://orcid.org/0000-0003-3693-9397 
Benedikt Mohr  https://orcid.org/0000-0001-9769-9986 
Sherif Abdelaziz Ibrahim  https://orcid.
org/0000-0001-6403-7345 
Francisco M. Goycoolea  https://orcid.org/0000-0001-7949-5429 
Mauro S.G. Pavão  https://orcid.org/0000-0002-1336-4271 
Juliana M. Motta  https://orcid.org/0000-0001-6687-6222 
Martin Götte  https://orcid.org/0000-0003-2360-2496 
R E FE R E N C E S
 1. Bernfield M, Götte M, Park PW, et al. Functions of cell surface hep-
aran sulfate proteoglycans. Annu Rev Biochem. 1999;68:729-777.
 2. Karamanos NK, Piperigkou Z, Theocharis AD, et al. Proteoglycan 
chemical diversity drives multifunctional cell regulation and thera-
peutics. Chem Rev. 1999;118:9152-9232.
 3. Häcker U, Nybakken K, Perrimon N. Heparan sulphate proteo-
glycans: the sweet side of development. Nat Rev Mol Cell Biol. 
2005;6:530-541.
 4. Espinoza-Sánchez NA, Götte M. Role of cell surface proteoglycans 
in cancer immunotherapy. Semin Cancer Biol. 2020;62:48-67.
 5. Blackhall FH, Merry CLR, Davies EJ, Jayson GC. Heparan sulfate 
proteoglycans and cancer. Br J Cancer. 2001;85:1094-1098.
 6. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles 
of heparan-sulfate glycosaminoglycans in cancer. Nat Rev Cancer. 
2002;2:521-528.
 7. Hassan H, Greve B, Pavão MS, Kiesel L, Ibrahim SA, Götte M. 
Syndecan-1 modulates β-integrin-dependent and interleukin-6- 
dependent functions in breast cancer cell adhesion, migration, and 
resistance to irradiation. FEBS J. 2013;280:2216-2227.
 8. Lindahl U, Gullberg KM, Kjellen L. Regulated diversity of heparan 
sulfate. J Biol Chem. 1998;273:24979-24982.
 9. Gallagher JT. Multiprotein signaling complexes: regional assembly 
on heparan sulphate. Biochem Soc Trans. 2006;34:438-441.
 10. Nakato H, Kimata K. Heparan sulfate fine structure and specificity of 
proteoglycan functions. Biochim Biophys Acta. 2002;1573:312-318.
 11. Dejima K, Takemura M, Nakato E, et al. Analysis of Drosophila glu-
curonyl C5-epimerase: implications for developmental roles of hep-
aran sulfate sulfation compensation and 2-O-sulfated glucuronic 
acid. J Biol Chem. 2013;288:34384-34393.
 12. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding 
sites in heparan sulfate. Annu Rev Biochem. 2002;71:435-471.
 13. Pinhal MA, Smith B, Olson S, Aikawa J, Kimata K, Esko JD. Enzyme 
interactions in heparan sulfate biosynthesis: uronosyl 5-epime-
rase and 2-O-sulfotransferase interact in vivo. Proc Natl Acad Sci. 
2001;98:12984-12989.
 14. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin 
Invest. 2001;108:169-173.
 15. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE. VEGF165-binding 
sites within heparan sulfate encompass two highly sulfated domains 
and can be liberated by K5 lyase. J Biol Chem. 2006;281:1731-1740.
 16. Maccarana M, Casu B, Lindahl U. Minimal sequence in heparin/hep-
aran sulfate required for binding of basic fibroblast growth factor. J 
Biol Chem. 1994;269:3903.
 17. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. 
Activating and inhibitory heparin sequences for FGF-2 (basic FGF). 
J Biol Chem. 1993;268:23906-23914.
 18. Smeds E, Feta A, Kusche-Gullberg M. Target selection of hep-
aran sulfate hexuronic acid 2-O-sulfotransferase. Glycobiology. 
2010;20:1274-1282.
 19. Rong J, Habuchi H, Kimata K, Lindahl U, Kusche-Gullberg M. 
Substrate specificity of the heparan sulfate hexuronic acid 
2-Osulfotransferase. Biochemistry. 2001;40:5548-5555.
 20. Bullock SL, Fletcher JM, Beddington RS, Wilson VA. Renal agenesis 
in mice homozygous for a gene trap mutation in the gene encoding 
heparan sulfate 2-sulfotransferase. Genes Dev. 1998;12:1894-1906.
 21. Kinnunen T, Huang Z, Townsend J, et al. Heparan 
2-O-sulfotransferase, hst-2, is essential for normal cell migration in 
Caenorhabditis elegans. Proc Natl Acad Sci. 2005;102:1507-1512.
 22. Afratis N, Gialeli C, Nikitovic D, et al. Glycosaminoglycans: key play-
ers in cancer cell biology and treatment. FEBS J. 2012;279:1177-1197.
 23. Yip GW, Smollich M, Gotte M. Therapeutic value of glycosamino-
glycans in cancer. Mol Cancer Ther. 2006;5:2139-2148.
 24. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel 
therapeutic targets. Nat Rev Cancer. 2005;5:526-542.
 25. Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for mem-
brane-bound and soluble syndecan-1 (CD138) in breast cancer pro-
gression. Carcinogenesis. 2009;30:397-407.
 26. Ledin J, Staatz W, Li JP, et al. Heparan sulfate structure in mice 
with genetically modified heparan sulfate production. J Biol Chem. 
2004;279:42732-42741.
 27. Götte M, Mohr C, Koo CY, et al. miR-145-dependent targeting of 
junctional adhesion molecule A and modulation of fascin expres-
sion are associated with reduced breast cancer cell motility and in-
vasiveness. Oncogene. 2010;29:6569-6580.
 28. Kemper B, Carl D, Höink A, von Bally G, Bredebusch I, 
Schnekenburger J. Modular digital holographic microscopy system 
for marker free quantitative phase contrast imaging of living cells. 
Proceedings of SPIE. 2006;6191:T-1-T-8.
 29. Kemper B, von Bally G. Digital holographic microscopy for life cell 
applications and technical inspection. Appl Opt. 2008;47:A52-A61.
     |  2921VIJAYA KUMAR et Al.
 30. Kemper B, Bauwens A, Vollmer A, et al. Label-free quantitative cell 
division monitoring of endothelial cells by digital holographic mi-
croscopy. J Biomedical Optics. 2010;153:036009.
 31. Mohamed HT, Untereiner V, Sockalingum GD, Brézillon S. 
Implementation of infrared and Raman modalities for glycos-
aminoglycan characterization in complex systems. Glycoconj J. 
2017;34:309-323.
 32. Mainreck N, Brézillon S, Sockalingum GD, Maquart FX, Manfait 
M, Wegrowski Y. Characterization of glycosaminoglycans by tan-
dem vibrational microspectroscopy and multivariate data analysis. 
Methods Mol Biol. 2012;836:117-130.
 33. Mainreck N, Brézillon S, Sockalingum GD, Maquart FX, Manfait M, 
Wegrowski Y. Rapid characterization of glycosaminoglycans using a 
combined approach by infrared and Raman microspectroscopies. J 
Pharm Sci. 2011;100(2):441-450.
 34. Brézillon S, Untereiner V, Lovergne L, et al. Glycosaminoglycan pro-
filing in different cell types using infrared spectroscopy and imag-
ing. Anal Bioanal Chem. 2014;406(24):5795-5803.
 35. Weinberg R. Moving Out: Invasion and Metastasis. The Biology of 
Cancer. Chapter 14. New York, NY: Garland Science, Taylor & Francis 
Group, LLC; New York, NY; 2007:587-654.
 36. Fidler IJ. Review: biologic heterogeneity of cancer metastases. 
Breast Cancer Res Treat. 1987;9:17-26.
 37. Knelson EH, Nee JC, Blobe GC. Heparan sulfate signaling in cancer. 
Trends Biochem Sci. 2014;37:277-288.
 38. Quarto N, Amalric F. Heparan sulfate proteoglycans as transducers 
of FGF-2 signaling. J Cell Sci. 1994;107:3201-3212.
 39. Birchmeier W, Hülsken J, Behrens J. E-cadherin as an invasion sup-
pressor. Ciba Found Symp. 1995;189:124-136.
 40. Chen H, Paradies NE, Chaiken MF, Brackenbury R. E-cadherin me-
diates adhesion and suppresses cell motility via distinct mecha-
nisms. J Cell Sci. 1997;110:345-356.
 41. Parker C, Rampaul RS, Pinder SE, et al. E-cadherin as a prognostic 
indicator in primary breast cancer. Br J Cancer. 2001;85:1958-1963.
 42. Götte M, Kersting C, Radke I, Kiesel L, Wülfing P. An expression 
signature of syndecan-1 (CD138), E-cadherin and c-met is associ-
ated with factors of angiogenesis and lymphangiogenesis in ductal 
breast carcinoma in situ. Breast Cancer Res. 2007;9:R8.
 43. Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and func-
tion of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ 
pathways. Oncogene. 1999;18:7860-7872.
 44. Liu BY, Kim YC, Leatherberry V, Cowin P, Alexander CM. Mammary 
gland development requires syndecan-1 to create a beta-catenin/
TCF-responsive mammary epithelial subpopulation. Oncogene. 
2003;22:9243-9253.
 45. Vijaya Kumar AV, Salem Gassar E, Spillmann D, et al. HS3ST2 mod-
ulates breast cancer cell invasiveness via MAP kinase- and Tcf4 
(Tcf7l2)-dependent regulation of protease and cadherin expression. 
Int J Cancer. 2014;135:2579-2592.
 46. Burness ML, Grushko TA, Olopade OI. Epidermal growth factor 
receptor in triplenegative and basal-like breast cancer: promising 
clinical target or only a marker? Cancer J. 2010;16:23-32.
 47. Ashikari-Hada S, Habuchi H, Sugaya N, Kobayashi T, Kimata K. 
Specific inhibition of FGF-2 signaling with 2-O-sulfated octasaccha-
rides of heparan sulfate. Glycobiology. 2009;19:644-654.
 48. Cole CL, Hansen SU, Baráth M, et al. Synthetic heparan sulfate oli-
gosaccharides inhibit endothelial cell functions essential for angio-
genesis. PLoS One. 2010;5:e11644.
 49. Floer M, Götte M, Wild MK, et al. Enoxaparin improves the course 
of dextran sodium sulfate-induced colitis in syndecan-1-deficient 
mice. Am J Pathol. 2010;176:146-157.
 50. Ushakov VS, Tsidulko AY, de La Bourdonnaye G, et al. Heparan sul-
fate biosynthetic system is inhibited in human glioma due to EXT1/2 
and HS6ST1/2 down-regulation. Int J Mol Sci. 2017;18(11):2301.
 51. Krueger JS, Keshamouni VG, Atanaskova N, Reddy KB. Temporal 
and quantitative regulation of mitogen-activated protein ki-
nase (MAPK) modulates cell motility and invasion. Oncogene. 
2011;20:4209-4218.
 52. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a 
family of protein kinases with diverse biological functions. Microbiol 
Mol Biol Rev. 2004;68:320-344.
 53. Reddy KB, Krueger JS, Kondapaka SB, Diglio CA. Mitogen-activated 
protein kinase (MAPK) regulates the expression of progelatinase B 
(MMP-9) in breast epithelial cells. Int J Cancer. 1999;82:268-273.
 54. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 
41-/43-kDa mitogen-activated protein kinase pathway in human tu-
mors. Oncogene. 1999;18:813-822.
 55. Earp HS III, Calvo BF, Sartor CI. The EGF receptor family– multiple 
roles in proliferation, differentiation, and neoplasia with an empha-
sis on HER4. Trans Am Clin Climatol Assoc. 2003;114:315-333.
 56. Wang GK, Zhang W. The signaling network of tumor invasion. Histol 
Histopathol. 2005;20:593-602.
 57. Price DJ, Avraham S, Feuerstein J, Fu Y, Avraham HK. The inva-
sive phenotype in HMT-3522 cells requires increased EGF recep-
tor signaling through both PI 3-kinase and ERK 1,2 pathways. Cell 
Commun Adhes. 2002;9:87-102.
 58. Wan G, Wang F, Ding W, et al. APRIL induces tumorigenesis and 
metastasis of colorectal cancer cells via activation of the PI3K/Akt 
pathway. PLoS One. 2013;8:e55298.
 59. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of 
AKT kinases in cancer: implications for therapeutic targeting. Adv 
Cancer Res. 2005;94:29-86.
 60. Suarez-Cuervo C, Merrell MA, Watson L, et al. Breast cancer cells 
with inhibition of p38alpha have decreased MMP-9 activity and 
exhibit decreased bone metastasis in mice. Clin Exp Metastasis. 
2004;21:525-533.
 61. Park YL, Kim HP, Cho YW, et al. Activation of WNT/β-catenin 
signaling results in resistance to a dual PI3K/mTOR inhibitor in 
colorectal cancer cells harboring PIK3CA mutations. Int J Cancer. 
2019;144:389-401.
 62. Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of 
mTOR signalling steers cancer initiation and metastasis. Nature. 
2012;485:55-61.
 63. Leung EY, Kim JE, Askarian-Amiri M, Joseph WR, McKeage MJ, 
Baguley BC. Hormone resistance in two MCF-7 breast cancer cell 
lines is associated with reduced mTOR signaling, decreased gly-
colysis, and increased sensitivity to cytotoxic drugs. Front Oncol. 
2014;4:221.
 64. Yue W, Wang JP, Conaway M, Masamura S, Li Y, Santen RJ. 
Activation of the MAPK pathway enhances sensitivity of 
MCF-7 breast cancer cells to the mitogenic effect of estradiol. 
Endocrinology. 2002;143:3221-3229.
 65. Ohira T, Gemmill RM, Ferguson K, et al. WNT7a induces E-cadherin 
in lung cancer cells. PNAS. 2003;100:10429-10434.
 66. Christofori G, Semb H. The role of the cell-adhesion molecule 
E-cadherin as a tumor-suppressor gene. Trends Biochem Sci. 
1999;24:73-76.
 67. Weinberg R. The Biology of Cancer. New York, NY: Garland Science; 
2006:864.
 68. Loh CY, Chai JY, Tang TF, et al. The E-Cadherin and N-cadherin 
switch in epithelial-to-mesenchymal transition: signaling, therapeu-
tic implications, and challenges. Cells. 2019;8:1118.
 69. Cadwalader EL, Condic ML, Yost HJ. 2-O-sulfotransferase regu-
lates Wnt signaling, cell adhesion and cell cycle during zebrafish 
epiboly. Development. 2012;139:1296-1305.
 70. di Martino E, Kelly G, Roulson JA, Knowles MA. Alteration of cell-
cell and cell-matrix adhesion in urothelial cells: an oncogenic mech-
anism for mutant FGFR3. Mol Cancer Res. 2015;13:138-148.
2922  |     VIJAYA KUMAR et Al.
 71. Paget S. The distribution of secondary growths in cancer of the 
breast. Cancer Metastasis Rev. 1989;8:98-101.
 72. Guo Q, Xia B, Zhang F, et al. Tetraspanin CO-029 inhibits colorectal 
cancer celln movement by deregulating cell-matrix and cell-cell ad-
hesions. PLoS One. 2012;7:e38464.
 73. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. 
Epidermal-growth-factor receptor status as predictor of early recur-
rence of and death from breast cancer. Lancet. 1987;1:1398-1402.
 74. Ciardielloa F, Tortora G. Epidermal growth factor receptor (EGFR) 
as a target in cancer therapy: understanding the role of receptor 
expression and other molecular determinants that could influence 
the response to anti-EGFR drugs. Eur J Cancer. 2003;39:1348-1354.
 75. Eccles SA. The epidermal growth factor receptor/Erb-B/HER 
family in normal and malignant breast biology. Int J Dev Biol. 
2011;55:685-696.
 76. Schafer B, Gschwind A, Ullrich A. Multiple G-protein coupled re-
ceptor signals converge on the epidermal growth factor receptor to 
promote migration and invasion. Oncogene. 2004;23:991-999.
 77. Doehn U, Hauge C, Frank SR, et al. RSK is a principal effector of 
the RAS-ERK pathway for eliciting a coordinate promotile/in-
vasive gene program and phenotype in epithelial cells. Mol Cell. 
2009;35:511-522.
 78. Xu R, Ori A, Rudd TR, et al. Diversification of the structural determi-
nants of fibroblast growth factor–heparin interactions: implications 
for binding specificity. J Biol Chem. 2012;287:40061-40073.
 79. Ori A, Free P, Courty J, Wilkinson MC, Fernig DG. Identification 
of heparin-binding sites in proteins by selective labeling. Mol Cell 
Proteomics. 2009;8:2256-2265.
 80. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibro-
blast growth factor receptor activation. Cytokine Growth Factor Rev. 
2005;16:107-137.
 81. Harmer NJ. Insights into the role of heparan sulphate in fibroblast 
growth factor signaling. Biochem Soc Trans. 2006;34:442-445.
 82. Patel HV, Vyas AA, Vyas KA, et al. Heparin and heparan sulfate bind 
to snake cardiotoxin. Sulfated oligosaccharides as a potential target 
for cardiotoxin action. J Biol Chem. 1997;272:1484-1492.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Vijaya Kumar A, Brézillon S, Untereiner 
V, et al. HS2ST1-dependent signaling pathways determine 
breast cancer cell viability, matrix interactions, and invasive 
behavior. Cancer Sci. 2020;111:2907–2922. https://doi.
org/10.1111/cas.14539
